Otonomy OTO-6XX — Hair Cell Regeneration

Dear x,

Thank you for your inquiry regarding Otonomy’s clinical trials for hearing loss.

OTO-413: In February 2021, Otonomy announced plans to evaluate additional patients with hearing loss in an expansion of the Phase 1/2 clinical 3 trial that was initiated in September 2019. That part of the trial is planned to start in the second quarter of 2021.

OTO-510, OTO-6XX, and Gene Therapy (OTO-825) programs: Otonomy is currently not conducting clinical trials with these compounds as they are in the pre-clinical phase.

Please note Otonomy is not providing medical treatment advice. Any treatment-related questions regarding your condition should be directed to your healthcare provider. This information is being provided as a courtesy in response to your unsolicited request.

Otonomy is located in the United States and information through our Medical Information services is received in the United States. If you have questions about the privacy of your information, you may contact privacy@otonomy.com.

For any further questions, please contact Otonomy Medical Information at [insert phone number] between the hours of 8:00 AM to 7:00 PM ET (5:00 AM to 4:00 PM PT), Monday through Friday or via email at medinfo@otonomy.com.

Sincerely,
Alfred Tsiang, PharmD
Otonomy Medical Information